Aims: Doxorubicin (DOX) is widely used in cytostatic treatments, although it may cause cardiovascular dysfunction as a side effect. DOX treatment leads to enhanced free radical production that in turn cause DNA strand breakage culminating in poly(ADP-ribose) polymerase (PARP) activation, mitochondrial and cellular dysfunction. DNA nicks can activate numerous enzymes, such as PARP-2. Depletion of PARP-2 has been shown to result in a protective phenotype against free radical-mediated diseases suggesting similar properties in the case of DOX-induced vascular damage. 
Introduction
Doxorubicin (adriamicin, DOX) is a widely used antitumor drug exerting cardiovascular side effects that may culminate in irreversible degenerative cardiomyopathy and heart failure 1 . DOX-induced cardiovascular injury is linked to increased oxidative stress 2 as DOX can export electrons from the mitochondria via redox cycling creating radical species 3 . Although cardiac effects of DOX toxicity are well characterized, vascular damage is scarcely mapped and the molecular background is largely unknown. Vascular damage upon DOX treatment affects the aorta 4, 5 , and smaller arteries in the liver 6 and kidney 7, 8 . Furthermore, DOX impairs endothelial function 9 and promotes thrombosis 10 .
Free radical evoked DNA damage activates poly(ADP-ribose) polymerase (PARP)-1 that catabolizes NAD + in order to create poly(ADP-ribose) (PAR) polymers. PARP-1 activation leads to NAD + and consequently ATP-depletion provoking cell dysfunction and cell death 11 .
This PARP-1-mediated cell death pathway is active in DOX-induced toxicity and it is a major contributor to cardiac and vascular dysfunction 12, 13 . Therefore, pharmacological inhibition of PARP-1 proved to be advantageous under such circumstances 12, 13 . Upon DOX damage PARP inhibition partially restored vascular contractility 13 .
PARP-2 is a nuclear enzyme that can bind to DNA nicks and thereby become active 14 .
Upon activation it is capable of synthesizing PAR at the expense of NAD +14 . Moreover, delivery. Cellular measurements took place 7 hours after addition of DOX.
Measurement of thiobarbituric acid reactive species (TBARS)
The extent of oxidative stress was assessed by determining lipid peroxidation. Aortae were homogenized in 1.15% KCl. Homoganates were cleared and supernatants were used.
Supernatants were incubated at 90 o C for 45 mins with thibarbituric acid. After cooling to room temperature, absorbance at 532 nm was measured and normalized to protein content. Mitochondrial DNA content was determined in qPCR reactions using total DNA extract of cells or tissues as described in 19 . Primers are summarized in Supplementary Tables S1 and   S2 .
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed similarly as in 25 . In MOVAS cells chromatinbound proteins were fixed on DNA by formaldehyde. Nuclei were prepared and chromatin was sonicated in order to split DNA into shorter, ~500 bp fragments. PARP-2 bonded chromatin fragments were collected by immunoprecipitation using α-PARP-2 (Alexis, Lausen, Switzerland) and α-matrix-metalloproteinase-9 (Santa Cruz, Santa Cruz, CA, USA)
antibodies. Formaldehyde crosslinking was reversed by heating then DNA fragments were purified and amplified using SIRT1 promoter-specific primers by qPCR reaction (primers are indicated in the respective section of Supplementary materials). The results were expressed as a percentage of input.
Statistical analysis
Statistical significance was determined using Student's t-test. Error bars represent SEM unless stated otherwise.
Results

PARP-2 depletion counteracts vascular dysfunction
We investigated vascular functions after DOX-treatment in PARP-2 +/+ and -/-mice first.
We did not detect major differences in aortic reactivity between untreated (CTL) PARP-2 Endothelial function was assessed by the application of acetylcholine. Impaired reactivity of aortae to acetylcholine after DOX treatment in both PARP-2 +/+ and -/-mice indicated that the DOX-induced deterioration of endothelial function was independent of PARP-2 ( Fig. 1D) .
Moreover, sodium nitroprusside-induced vasorelaxation was not affected by either DOX treatment or by the deletion of PARP-2 ( Fig. 1E) , suggesting that blunted acetylcholine responses were not related to impaired NO reactivity of smooth muscle cells.
Taken together, our physiological data suggested a role for PARP-2 in DOX-evoked vascular dysfunction and implicated smooth muscle as a potential target. This notion was further supported by decreased smooth muscle actin immunoreactivity in PARP-2 +/+ mice after DOX treatment suggesting a loss of smooth muscle cells, which was not the case in (Fig. 1F) . Importantly, these data identify smooth muscle dysfunction as a novel mechanism of DOX-induced vascular damage. In our following experiments, we employed an aortic smooth muscle cell line (MOVAS) to reveal the potential mechanisms for
PARP activity is not altered upon PARP-2 depletion
Reactive oxygen species produced by mitochondrial redox cycling of DOX has previously been shown to trigger PARP activation and PAR synthesis. Moreover, ablation of PARP-1 resulted in suppressed PAR synthesis and protection against DOX-evoked cardiovascular damage 12, 13 . Since PARP-2 also possesses poly(ADP-ribose) polymerase activity 14 we set out to investigate the role of PARP-2 in DOX-evoked PAR synthesis and vascular smooth muscle dysfunction.
We detected free radical production in both aortae and MOVAS cells upon DOX treatment ( Fig. 2A and 2B ). Moreover, free radical production was increased upon PARP-2 ablation. Enhanced free radical production resulted in DNA strand breakage in both types of samples as shown by increased TUNEL staining ( Fig. 2C and 2D ). However, there was no apparent change in TUNEL positivity upon PARP-2 ablation or depletion neither in mice, nor in MOVAS cells ( Fig. 2C and 2D ). The level of DOX-induced PARP activity was not different between PARP-2 +/+ and -/-mice (Fig. 2E) . Similarly, there was no marked difference in PARP activation between MOVAS cells in which PARP-2 was silenced by specific shRNA (shPARP-2) or its unspecific scrambled version (scPARP-2) (Fig. 2F) . These results suggested a dominant role for PARP-1 in DOX-evoked PAR formation. PAR was detected only in smooth muscle cells suggesting that DOX-evoked endothelial dysfunction is both PARP-1 and PARP-2 independent. Cellular NAD + depletion was also similar in control and PARP-2-depleted cells (Fig. 2G) suggesting again a minor, if any role for PARP-2 in this process. Taken together, PARP-2 depletion or deletion results in vascular protection without affecting DOX-induced overall PARP activity.
SIRT1 overexpression counteracts DOX toxicity
Apparently the protection provided by the depletion of PARP-2 has a different mechanism than the one responsible for the protective effect of PARP-1 inhibition. 33 . Accordingly, we tested whether increased SIRT1 expression might be the key protective mechanism against DOX treatment in PARP-2 -/-mice.
Disruption, or depletion of PARP-2 in aortae or in MOVAS cells (Fig. 3A-B ) resulted in an increase in SIRT1 mRNA and SIRT1 protein levels ( Fig. 3C-D) . This increase in SIRT1 expression was associated with the induction of the SIRT1 promoter (Fig. 3E) , which was mediated by a decrease in the occupancy of SIRT1 promoter by PARP-2 (Fig. 3F ).
SIRT1 activation enhances mitochondrial oxidative capacity of multiple metabolic tissues 31 . We detected increased mitochondrial DNA content both in the aorta and in MOVAS cells upon the deletion or depletion of PARP-2 (Fig. 4A, C) . Increased mitochondrial biogenesis was further supported by increased expression of genes involved in biological oxidation (Foxo1, ATP5g1, ndufa2, ndufb5) in aortae (Fig. 4B ). Higher expression of oxidative genes was maintained in PARP-2 -/-mice even after DOX treatment compared to +/+ mice (Fig. 4B ). To provide further evidence for the involvement of increased mitochondrial activity, mitochondrial membrane potential and oxygen consumption was determined in shPARP-2 MOVAS cells displayed similar mitochondrial membrane potential, but PARP-2 silencing resulted in slightly higher oxygen consumption rate. Oxygen consumption and free radical production increased at 7 hours after DOX treatment (Fig. 2B, Fig. 4D ) suggesting mitochondrial uncoupling and mitochondrial dysfunction. Mitochondrial membrane potential in scPARP-2 MOVAS cells increased in line with the increment of DOX concentration suggesting mitochondrial hyperpolarization (Fig. 4E) . Hyperpolarization of mitochondrial membrane has been described as an early event in apoptosis supporting impaired mitochondrial biogenesis 34 . Overall, oxygen consumption was higher in shPARP-2 MOVAS cells than in scPARP-2 cells. The difference in oxygen consumption increased upon DOX treatment similarly, while mitochondrial hyperpolarization was much lower suggesting milder mitochondrial damage (Fig. 4D, E) . 
5.).
To our best knowledge, this is the first study reporting the protective properties of SIRT1-induced mitochondrial biogenesis in blood vessels. Indeed, SIRT1 has been shown to act as a cardioprotective factor 33, [35] [36] [37] [38] . Pharmacological activation of SIRT1 by resveratrol has been demonstrated to induce mitochondrial activity in cardiomyocytes 33 . However, it must be noted that results obtained with resveratrol can not simply be attributed to SIRT activation. as the specificity of resveratrol towards SIRT1 is debated 39 . Moreover, it may act as a free radical scavenger 40 , hence it may eliminate reactive species released by DOX. Therefore, resveratrol may interfere with PARP-1 activation by quenching free radicals and hence protect mitochondria, or may act on unknown pharmacological targets to confer protection. As Danz and colleagues 33 have detected a complete loss of free radical production upon resveratrol treatment, it cannot be ruled out that resveratrol treatment acted upstream of mitochondrial biogenesis induction interfering with PARP-1 activation and provided protection through blunting PARP-1-mediated cell death.
In the heart, SIRT1 can activate other protective mechanisms. As indicated in Fig. 5 , SIRT1 may deacetylate p53 and induce the expression of Bax family proteins 41 . SIRT1 may also impair PARP-1 activation and the consequent cellular dysfunction through deacetylating PARP-1 38 or by consuming NAD +37 . However, we did not observe differences in PARP activity or NAD + consumption in PARP-2 depleted smooth muscle cells or in PARP-2 -/-aorta, but observed an upregulation of SIRT1 and increased mitochondrial protein expression and function. These apparent differences suggest that the mechanism of vascular protection may consist of different pathways than the ones observed in the heart. Importantly, however, by guest on September 16, 2011 
